3 Dirt Cheap Dividend Stocks Worth Buying in October

The article identifies Pfizer, Bristol Myers Squibb, and UnitedHealth as discounted healthcare dividend opportunities, citing valuations of roughly 9x forward earnings for Pfizer and Bristol Myers and 19x for UnitedHealth. Pfizer yields 6% with $11.7B of cash and short-term investments, while Bristol Myers yields 4% and faces 2028 patent losses for Eliquis and Opdivo, which represented about half of prior-year sales. Analysts project annual earnings growth of about 5% for Pfizer and more than 13% for UnitedHealth over the next three to five years, supporting the article's constructive income-investing view despite company-specific risks.

Analysis

The opportunity is not a broad healthcare-beta trade; it is dispersion among companies whose earnings risk is being priced differently. PFE's valuation leaves little room for pipeline or acquired-product execution disappointments, while its dividend consumes most free cash flow after interest, restructuring and business-development needs. The relevant catalyst over the next 1-3 months is not the headline yield but quarterly non-COVID revenue growth, oncology-launch uptake, and management's ability to maintain leverage reduction without curtailing buybacks or dividend growth.

BMY's 2028 loss-of-exclusivity exposure should keep its multiple capped until the market can underwrite a credible replacement-revenue bridge. That creates a potential 6-18 month rerating only if newer assets demonstrate durable volume growth and the company deploys excess cash toward debt reduction rather than dilutive M&A; otherwise, the stock risks becoming a yield trap as consensus estimates roll down ahead of the cliff. Generic/biosimilar timing, especially around the two core franchises, is the key structural falsifier.

UNH is the higher-quality but more crowded recovery vehicle. Its incremental earnings sensitivity is dominated by Medicare Advantage utilization, medical-cost trend and reimbursement rather than membership growth; a modest medical-loss-ratio miss can erase several quarters of operating leverage. The contrarian view is that political and regulatory risk deserves a persistent valuation discount: any adverse CMS rate decision, DOJ escalation, or evidence of sustained elevated utilization can interrupt the rerating within days, despite otherwise resilient cash generation.

The article is low-information promotional content, so no immediate catalyst is created. Prefer waiting for earnings revisions and margin datapoints rather than purchasing healthcare exposure solely on stated valuation multiples or dividend yields.

Key Decisions for Investors

• Maintain a watchlist, not a fresh PFE long, into the next earnings print. Upgrade only if ex-COVID revenue growth and 2027 guidance support positive EPS revisions while net-debt reduction remains on track; exit/avoid if dividend coverage deteriorates further or management funds capital returns with incremental borrowing.
• Consider a 6-12 month pair: long BMY / short PFE in equal dollar exposure after confirming BMY's growth-portfolio trajectory. BMY offers lower near-term payout stress, while PFE carries greater execution dependence; invalidate if BMY's replacement-drug sales miss guidance for two consecutive quarters or its 2028 revenue bridge weakens.
• Use UNH only as a tactical 1-3 month long following evidence that medical-cost trend is normalizing, preferably versus a diversified managed-care proxy such as XLV rather than outright. Target a rerating from improving MLR guidance; cut exposure on a material Medicare Advantage rate headwind, utilization-driven margin miss, or new enforcement action.
• For defensive healthcare exposure, favor diversified large-cap pharma/biotech ETFs such as XLV over concentrated dividend longs until upcoming earnings establish whether estimate revisions have bottomed. The article's modest sentiment and low expected impact do not justify paying option premium.